Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In the next few months, the first Phase 3 COVID-19 vaccine trials – the majority of them in upper-middle or high-income countries and in specific target populations like young adults – will report their results. How relevant will their study results be for low-resource settings?

Headshots of webinar speakers Rebecca Kahn, Rebecca Grais, Cherry Kang and James Watson

On 27 Oct, the COVID-19 Clinical Research Coalition (hosted by DNDi) and MORU co-organized an online webinar panel, Applicability of COVID-19 vaccine trial results to low- and middle-income countries. Moderator Dr James Watson (MORU) and a panel of speakers examined whether criteria relevant for low- and middle-income countries have been taken into account when planning these studies and in determining how to define a “successful” vaccine.

The speakers and their topics in the Applicability of COVID-19 vaccine trial results to low-and-middle-income countries webinar are: 

Designing & interpreting vaccine trials for epidemics with mild and asymptomatic infections, Dr Rebecca Kahn, Harvard University, USA

Trialing vaccines in outbreaks and crises: some lessons learned, Dr Rebecca Grais, Epicentre, France

The impact of trial design on vaccine uptake: Regulatory approval, vaccine acceptability and other issues, Prof. Gagandeep Kang, Christian Medical College, Vellore, India & Steering Committee Member of the COVID-19 Clinical Research Coalition.

Similar stories

Tropical Medicine DPhil Students awarded NDM Prize

Every year, the Nuffield Department of Medicine awards NDM Prizes to our most outstanding students. This year, Mo yin and Rebecca Inglis (both at MORU) were highly commended in the category NDM Overall Prize, for conducting research with an outstanding impact. Will Schilling (MORU) received a prize as first year DPhil student, and Mohammad Ali (OCGHR) as second year DPhil student. Our warmest congratulations to you all!

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.